KEY POINTS
- CROP was a prospective, two-center, single-arm phase I/II trial evaluating comprehensive stereotactic body radiotherapy (SBRT) plus intermittent androgen deprivation therapy (ADT) for oligometastatic hormone-sensitive prostate cancer. Between 2015 and 2019, 89 evaluable patients with 171 metastases were enrolled, including 33 patients (37.1%) with synchronous and 56 (62.9%) with metachronous metastatic disease. Eligibility permitted up to five metastases, with no more than three in any organ system, identified predominantly using conventional imaging. Median follow-up was 74.7 months.
- All known disease sites were treated with SBRT, followed by an intermittent systemic treatment strategy. The prostate, when present and previously untreated, received 35–40 Gy in five fractions; nodal metastases received 30–40 Gy in five fractions, nonspinal bone metastases 30–40 Gy in five fractions or 24 Gy in two fractions, and spinal metastases 24–28 Gy in two fractions or 30–40 Gy in four to five fractions. Patients received 12 months of ADT, which was subsequently discontinued and restarted when PSA exceeded 10 ng/mL, new metastases developed, or clinical circumstances warranted earlier treatment. No patient received chemotherapy or androgen receptor pathway inhibitor (ARPI) intensification during the initial ADT course.
- The primary safety endpoint showed a relatively low incidence of severe SBRT-related toxicity. Six patients (6.7%, 95% CI 2.5–14.1%) experienced grade 3 adverse events, comprising five radiation-associated vertebral fractures and one urinary obstruction after prostate SBRT. No grade ≥3 acute toxicity or grade 4–5 treatment-related events were documented. The vertebral fractures indicate that the potential benefits of treating all metastatic sites must be balanced against skeletal toxicity, particularly during androgen suppression.
- Local control of irradiated disease was favorable, but new metastatic progression remained frequent. The five-year cumulative incidence of local failure was 8.8% (95% CI 5.2–13.7%), whereas the cumulative incidence of developing new metastases reached 56.1% (95% CI 44.9–65.8%). Among 55 patients who developed new metastases at first radiographic progression, 89.0% had five or fewer new lesions, permitting consideration of further metastasis-directed treatment. Subsequent irradiation of new metastatic sites was performed in 36 patients (40.5%) before the development of castration-resistant disease.
- Intermittent ADT allowed some patients to remain off hormonal treatment during long-term follow-up. The five-year cumulative incidence of restarting ADT was 59.7% (95% CI 48.4–69.2%), and 55 patients (61.8%) eventually restarted treatment. Testosterone recovery reached 82.9% at three years, with a median recovery time of 18.6 months. At the final assessment, 35 patients (39.3%) were alive with hormone-sensitive disease and were not receiving ADT, although this does not mean that all had remained continuously treatment-free after the initial course.
- Long-term disease control was substantially less favorable than overall survival. Five-year failure-free survival, defined by the absence of biochemical or radiographic progression, ADT restart, or death, was 15.2% (95% CI 9.2–25.0%). Five-year cumulative incidence of castration-resistant prostate cancer was 22.8% (95% CI 14.7–32.1%), while five-year overall survival was 78.2% (95% CI 70.0–87.4%). These outcomes suggest durable disease control without further treatment in a minority, but do not demonstrate a curative effect or comparative benefit from intermittent therapy.
- PSA nadir after the initial treatment course was associated with subsequent outcomes. Median PSA nadir was 0.03 ng/mL, and 72/89 patients (80.9%) achieved a nadir of ≤0.2 ng/mL. Higher PSA nadir was associated with increased risk of castration-resistant disease (subdistribution HR 1.384, 95% CI 1.109–1.726; p=0.004) and worse overall survival (HR 1.547, 95% CI 1.239–1.930; p=0.001) in exploratory univariable analyses using log-transformed PSA. The 0.2-ng/mL threshold was identified retrospectively and has not been validated for treatment selection. Importantly, 88.8% of patients were staged using conventional imaging without additional PET, and no randomized comparator assessed continuous ADT with modern ARPI intensification.
CLINICAL TAKEAWAY
Comprehensive SBRT combined with intermittent ADT achieved favorable long-term survival and relatively low severe treatment-related toxicity in selected patients with conventionally staged oligometastatic hormone-sensitive prostate cancer. However, most patients ultimately experienced progression or resumed systemic therapy, and the single-arm design cannot establish that intermittent ADT is equivalent to contemporary continuous intensified treatment. PSA nadir may help identify patients suitable for future risk-adapted trials, but should not yet determine systemic treatment de-escalation.
SOURCE
International Journal of Radiation Oncology, Biology, Physics